FDA approves new drug for inhaled anthrax

Federal health officials say they approved a new injectable drug from Human Genome Sciences to treat inhalable anthrax.

The Food and Drug Administration says raxibacumab will provide an alternative to antibiotic drugs that are currently the standard treatment for .

Inhalation anthrax occurs when people breathe in the spores of bacteria. The infection is treated with a 60-day course of antibiotics.

Raxibacumab is a manmade protein that blocks toxins produced by anthrax. It mimics naturally occurring antibodies in the human body that find and destroy harmful substances.

The FDA approved the drug based on effectiveness studies in monkeys and rabbits that were infected with Anthrax. The drug's safety was tested in 326 healthy human volunteers.

The drug was developed by GlaxoSmithKline PLC's Human Genome Sciences.


Explore further

Rare anthrax case diagnosed in Minnesota

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA approves new drug for inhaled anthrax (2012, December 14) retrieved 20 September 2019 from https://medicalxpress.com/news/2012-12-fda-drug-inhaled-anthrax.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more